| 10.38 -0.21 (-1.98%) | 10-01 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 150.47 | 1-year : | 155.54 |
| Resists | First : | 128.83 | Second : | 133.17 |
| Pivot price | 127.16 |
|||
| Supports | First : | 121.8 | Second : | 101.34 |
| MAs | MA(5) : | 123.39 |
MA(20) : | 126.94 |
| MA(100) : | 122.32 |
MA(250) : | 108.57 |
|
| MACD | MACD : | -0.7 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 6.2 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 133.8 | Low : | 84.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HLI ] has closed above bottom band by 23.1%. Bollinger Bands are 18.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 124.3 - 124.99 | 124.99 - 125.63 |
| Low: | 120.55 - 121.47 | 121.47 - 122.32 |
| Close: | 122.44 - 123.77 | 123.77 - 124.99 |
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.
Tue, 21 Sep 2021
Hancock Jaffe to change name and narrow strategic focus (NASDAQ:HJLI) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 52 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 107.1 (%) |
| Shares Short | 1,310 (K) |
| Shares Short P.Month | 1,850 (K) |
| EPS | 3.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.59 |
| Profit Margin | 14 % |
| Operating Margin | 18.8 % |
| Return on Assets (ttm) | 9.1 % |
| Return on Equity (ttm) | 15.6 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 35.14 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 15.6 % |
| Operating Cash Flow | 341 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 31.81 |
| PEG Ratio | 3.2 |
| Price to Book value | 4.83 |
| Price to Sales | 3.52 |
| Price to Cash Flow | 18.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|